Comparative Pharmacology
Head-to-head clinical analysis: V CILLIN versus V CILLIN K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: V CILLIN versus V CILLIN K.
V-CILLIN vs V-CILLIN K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G (V-CILLIN) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin activation, leading to cell lysis.
Penicillin V exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
250-500 mg orally every 8 hours or 500 mg every 12 hours for mild to moderate infections.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life ~30-60 minutes in normal renal function; prolonged in renal impairment (up to 10 hours in anuria).
0.5–1 hour (normal renal function); prolonged to 2–6 hours in renal impairment.
Primarily renal (60-70% unchanged via tubular secretion); minor biliary/fecal elimination (<10%).
Renal: 60-90% unchanged via tubular secretion and glomerular filtration; minor biliary/fecal: <10%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic